New immunisation reference page: Live-attenuated vaccines in patients receiving regular red blood cell transfusions
Patients receiving regular red blood cell transfusions to treat chronic medical conditions such as transfusion dependent thalassaemia, sickle cell disease, inherited chronic haemolytic anaemias, or inherited bone marrow failure syndromes are often left unprotected from vaccine preventable diseases due to not meeting the required intervals between red blood cell transfusions. Evidence in this space is limited, however specialist advice suggests that immunisation of this patient group with live-attenuated vaccines is safe and recommended. As such, MVEC has created a new reference page outlining the process of immunisation for these patients. Please refer to एमवीईसी: नियमित लाल रक्त कोशिका संक्रमण प्राप्त करने वाले मरीजों में जीवित-क्षीण टीके अधिक जानकारी के लिए।
Zostavax safety advisory
The Therapeutic Goods Administration (TGA) have reiterated their advice that Zostavax should not be administered to immunocompromised individuals as it is associated with a risk of mild-serious complications. This advice follows a report of a new case of a patient who was taking hydroxychloroquine and a low dose of prednisolone who died three weeks after receiving the Zostavax vaccine. Whilst it was found that the Zostavax was administered in line with existing recommendations it is important that health professionals are aware of the potential of this kind of very rare adverse event.
Read more here:
And for more information on Zoster and to access the Zostavax GP Decision Aid refer to the एमवीईसी: ज़ोस्टर immunisation reference page.
एमवीईसी टीकाकरण संदर्भ पृष्ठ अद्यतन एनआईपी परिवर्तनों को दर्शाता है 1 जुलाई 2020
हमने 1 जुलाई 2020 तक राष्ट्रीय टीकाकरण कार्यक्रम (एनआईपी) में हुए परिवर्तनों को दर्शाने के लिए निम्नलिखित एमवीईसी टीकाकरण संदर्भ पृष्ठों को अपडेट किया है:
- एमवीईसी: आदिवासी और टोरेस स्ट्रेट आइलैंडर टीकाकरण सिफारिशें
- एमवीईसी: एस्प्लेनिया
- एमवीईसी: हृदय रोग वाले बच्चे
- एमवीईसी: मेनिंगोकोकल रोग और टीके
- एमवीईसी: मेनिंगोकोकल टीके विशेष जोखिम और इम्यूनोसप्रेस्ड रोगियों में
- एमवीईसी: प्रीटरम शिशु टीकाकरण
- एमवीईसी: 20 वर्ष की आयु तक खरीद के लिए अनुशंसित अतिरिक्त टीके (अनफंडेड)
इन्फ्लुएंजा का टीका और अंडा एलर्जी
अंडा एलर्जी (अंडे एनाफिलेक्सिस सहित) के साथ और बिना इन्फ्लूएंजा टीकाकरण के संभावित और पूर्वव्यापी अध्ययन के आधार पर, अंडे की एलर्जी की उपस्थिति इन्फ्लूएंजा के टीके के लिए एलर्जी प्रतिक्रियाओं के जोखिम को नहीं बढ़ाती है और इसे सामुदायिक टीकाकरण सेटिंग में प्रशासित किया जा सकता है, जैसा कि एक एकल खुराक, अनुशंसित 15 मिनट अवलोकन अवधि के बाद।
अधिक जानकारी के लिए कृपया निम्नलिखित देखें:
New immunisation reference page: Intradermal vaccination
Intradermal vaccination is the delivery of vaccines into the outer layers of the skin and is used for a small number of vaccines such as BCG and Hepatitis B (for non-responders).
To find out more about intradermal vaccination, which vaccines can be given this way and how intradermal vaccines are administered, please see our new immunisation reference page, MVEC: इंट्राडर्मल टीकाकरण.
Pharmacist Immuniser Update
Victorian Pharmacist Immunisers are now authorised to administer influenza vaccines to patients 10-years and older and pertussis-containing, measles-mumps-rubella and meningococcal ACWY vaccines to people aged 15 years and older.
For more information see the most recent DHHS Secretary Approval: Pharmacist Immuniser.
See also our updated MVEC: Pharmacist Immuniser page और यह एमवीईसी: इन्फ्लुएंजा वैक्सीन सिफारिशें page.
How do I know which influenza brand to use in the 2020 influenza season?
| आयु वर्ग | Brand and dose | |||||
|---|---|---|---|---|---|---|
| FluQuadri® 0.5ml (Sanofi) | Vaxigrip Tetra® 0.5ml (Sanofi) | Fluarix Tetra® 0.5ml (GSK) | Afluria Quad® 0.5ml (Seqirus) | Influvac Tetra® 0.5ml (Mylan) | Fluad® Quad 0.5ml (Seqirus) | |
| <6-months | Too young to receive vaccine (N/A) | |||||
| 6 to 35-months (<3-years) *¥ | 0.5 मि.ली | 0.5 मि.ली | 0.5 मि.ली | लागू नहीं | लागू नहीं | लागू नहीं |
| ≥3-years to <5-years *¥ | 0.5 मि.ली | 0.5 मि.ली | 0.5 मि.ली | लागू नहीं | 0.5 मि.ली | लागू नहीं |
| ≥5 to <65-years *¥ | 0.5 मि.ली | 0.5 मि.ली | 0.5 मि.ली | 0.5 मि.ली | 0.5 मि.ली | लागू नहीं |
|
≥65-years |
0.5 मि.ली | 0.5 मि.ली | 0.5 मि.ली | 0.5 मि.ली | 0.5 मि.ली | 0.5ml# |
For further information on seasonal influenza vaccines in 2020, refer to our MVEC resources: Influenza vaccine recommendations page
Influenza vaccine 2020 FAQ's
MVEC’s Frequently Asked Questions for the 2020 Influenza season are now available online
To view our reference page please click on the following link:
MVEC: Influenza vaccines: Frequently asked questions
MVEC Influenza recommendations 2020
For information on influenza immunisation for the 2020 season, including age specific brands, dosing guidelines and advice for at risk groups, please refer to:
MVEC: Influenza vaccine recommendations 2020
New immunisation reference page: Gelatin allergy and vaccines
Gelatin in vaccines can cause allergic reactions therefore people with severe allergies to gelatin should avoid gelatin-containing vaccines. See our new Gelatin allergy and vaccines reference page for more information.
MVEC: Gelatin allergy & vaccines